Soleno Therapeutics (SLNO) CFO granted stock options and RSUs in Form 4

Rhea-AI Filing Summary

Soleno Therapeutics chief financial officer Jennifer Fulk reported equity awards tied to her compensation. On March 2, 2026, she acquired options covering 67,660 shares of common stock through an exercise or conversion of a derivative security and was granted 39,200 shares of common stock in the form of restricted stock units.

The RSUs vest in four equal installments of 25% each on March 2, 2027, March 2, 2028, March 2, 2029, and March 2, 2030, contingent on her continued service. The option vests with one-fourth on March 2, 2027, then in equal monthly installments over the following 36 months, also conditioned on continued service.

Insider Trade Summary

67,660 shares exercised/converted

Mixed 2 txns

Insider Fulk Jennifer

Role CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Exercise	Employee stock option (right to buy)	67,660	$0.00	--
Grant/Award	Common Stock	39,200	$0.00	--

Holdings After Transaction: Employee stock option (right to buy) — 67,660 shares (Direct); Common Stock — 39,200 shares (Direct)

Footnotes (1)

1. These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. 25% of RSUs shall vest on each of March 2, 2027, March 2, 2028, March 2, 2029 and March 2, 2030, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date. One-fourth of the shares subject to the option shall vest on March 2, 2027 and one forty-eighth of the shares subject to the option shall vest each month thereafter on the same day of the month, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fulk Jennifer

(Last) (First) (Middle)

100 MARINE PARKWAY, SUITE 400

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SOLENO THERAPEUTICS INC [ SLNO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		A		39,200(1)	A	$0	39,200(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$39.06	03/02/2026		M		67,660		(2)	03/02/2036	Common Stock	67,660	$0	67,660	D

Explanation of Responses:

1. These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. 25% of RSUs shall vest on each of March 2, 2027, March 2, 2028, March 2, 2029 and March 2, 2030, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date.

2. One-fourth of the shares subject to the option shall vest on March 2, 2027 and one forty-eighth of the shares subject to the option shall vest each month thereafter on the same day of the month, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date.

	/s/ Anish Bhatnagar, Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Soleno Therapeutics (SLNO) report for Jennifer Fulk?

Soleno Therapeutics reported that CFO Jennifer Fulk acquired equity awards on March 2, 2026, including 67,660 option shares and 39,200 restricted stock units. These awards form part of her compensation and vest over several years, subject to continued service.

How many stock options did the Soleno Therapeutics CFO receive in the latest Form 4?

The Soleno Therapeutics CFO received options relating to 67,660 shares of common stock. One-fourth vests on March 2, 2027, with the remaining shares vesting monthly over the next 36 months, assuming she continues as a service provider under the equity plan.

What restricted stock unit (RSU) grant was disclosed for Soleno Therapeutics (SLNO) CFO?

The filing shows a grant of 39,200 restricted stock units to the CFO. Each RSU represents one share of common stock and vests 25% annually on March 2 of 2027, 2028, 2029, and 2030, provided she remains a service provider on each vesting date.

When do the Soleno Therapeutics CFO’s RSUs vest according to the Form 4 filing?

The CFO’s RSUs vest in four equal tranches: 25% on March 2, 2027, 25% on March 2, 2028, 25% on March 2, 2029, and 25% on March 2, 2030, each contingent on her continued service under the company’s 2014 Equity Incentive Plan.

What is the vesting schedule for the Soleno Therapeutics CFO stock options?

For the CFO’s options on 67,660 shares, one-fourth vests on March 2, 2027. The remaining three-fourths vest in equal monthly installments over the following 36 months on the same day, assuming she continues as a service provider throughout the vesting period.